Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Chan

Showing results (341-350 of 449) with videos related to

Pageof 45
Sort By:
Journal of Psychosomatic Research|February 25, 2021
Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?Stephanie Rodgers, Pasquale Calabrese, Vladeta Ajdacic-Gross, et al.
Communications Biology|May 3, 2022
Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patientsDiego Cantoni, Martin Mayora-Neto, Nazia Thakur, et al.
Multiple Sclerosis and Related Disorders|August 22, 2025
Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC scoreGabriel Bsteh, Vincenzo Introcaso, Christiane Gradl, et al.
Medrxiv : the Preprint Server for Health Sciences|May 1, 2026
Evaluating Individual Level Performance of Polygenic Risk Scores Using Early Onset High Genetic Risk Coronary Artery Disease as a BenchmarkShengxin Liang, Min Seo Kim, Yang Sui, et al.
Plos One|May 3, 2011
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disordersAiden Haghikia, Moritz Perrech, Bartosz Pula, et al.
Multiple Sclerosis and Related Disorders|August 7, 2022
Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis RegistryMina Stanikić, Anke Salmen, Andrew Chan, et al.
Therapeutic Advances in Neurological Disorders|August 4, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS StudyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Journal of Medical Virology|June 15, 2022
Human seasonal coronavirus neutralization and COVID-19 severityDavid A Wells, Diego Cantoni, Martin Mayora-Neto, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 25, 2023
Opto-Lipidomics of TissuesMagnus Jensen, Shiyue Liu, Elzbieta Stepula, et al.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Pageof 45

Showing results (341-350 of 449) with videos related to

Sort By:
Pageof 45
Journal of Psychosomatic Research|February 25, 2021
Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?Stephanie Rodgers, Pasquale Calabrese, Vladeta Ajdacic-Gross, et al.
Communications Biology|May 3, 2022
Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patientsDiego Cantoni, Martin Mayora-Neto, Nazia Thakur, et al.
Multiple Sclerosis and Related Disorders|August 22, 2025
Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC scoreGabriel Bsteh, Vincenzo Introcaso, Christiane Gradl, et al.
Medrxiv : the Preprint Server for Health Sciences|May 1, 2026
Evaluating Individual Level Performance of Polygenic Risk Scores Using Early Onset High Genetic Risk Coronary Artery Disease as a BenchmarkShengxin Liang, Min Seo Kim, Yang Sui, et al.
Plos One|May 3, 2011
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disordersAiden Haghikia, Moritz Perrech, Bartosz Pula, et al.
Multiple Sclerosis and Related Disorders|August 7, 2022
Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis RegistryMina Stanikić, Anke Salmen, Andrew Chan, et al.
Therapeutic Advances in Neurological Disorders|August 4, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS StudyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Journal of Medical Virology|June 15, 2022
Human seasonal coronavirus neutralization and COVID-19 severityDavid A Wells, Diego Cantoni, Martin Mayora-Neto, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 25, 2023
Opto-Lipidomics of TissuesMagnus Jensen, Shiyue Liu, Elzbieta Stepula, et al.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Pageof 45